Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors (2017)
- Authors:
- USP affiliated authors: SILVA, ALFREDO RIBEIRO DA - FMRP ; ANDRADE, JURANDYR MOREIRA DE - FMRP ; CARRARA, HELIO HUMBERTO ANGOTTI - FMRP ; TIEZZI, DANIEL GUIMARÃES - FMRP
- Unidade: FMRP
- DOI: 10.1590/1414-431x20165674
- Subjects: NEOPLASIAS MAMÁRIAS; QUIMIOTERAPIA ADJUVANTE; PROGNÓSTICO
- Keywords: Neoadjuvant chemotherapy; Trastuzumab; Pathologic complete response; Predictive factors of response; Prognosis
- Language: Inglês
- Imprenta:
- Publisher place: Ribeirão Preto
- Date published: 2017
- Source:
- Título: Brazilian Journal of Medical and Biological Research
- ISSN: 0100-879X
- Volume/Número/Paginação/Ano: v. 50, n. 2, art. 5674, 2017
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
BUZATTO, I. P. C. et al. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, v. 50, n. 2, 2017Tradução . . Disponível em: https://doi.org/10.1590/1414-431x20165674. Acesso em: 31 mar. 2026. -
APA
Buzatto, I. P. C., Ribeiro-Silva, A., Andrade, J. M. de, Carrara, H. H. A., & Tiezzi, D. G. (2017). Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, 50( 2). doi:10.1590/1414-431x20165674 -
NLM
Buzatto IPC, Ribeiro-Silva A, Andrade JM de, Carrara HHA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors [Internet]. Brazilian Journal of Medical and Biological Research. 2017 ; 50( 2):[citado 2026 mar. 31 ] Available from: https://doi.org/10.1590/1414-431x20165674 -
Vancouver
Buzatto IPC, Ribeiro-Silva A, Andrade JM de, Carrara HHA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors [Internet]. Brazilian Journal of Medical and Biological Research. 2017 ; 50( 2):[citado 2026 mar. 31 ] Available from: https://doi.org/10.1590/1414-431x20165674 - Quality of life in women with breast cancer treated with or without chemotherapy
- Cancer stem cells and lymph node metastasis in early stage breast cancer
- Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up
- Clinicopathological characteristics and recurrence risk in patients with ductal carcinoma in situ of the breast
- Idade como fator independente de prognóstico no câncer de mama
- Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer
- Tumor neuroendócrino primário de mama: relato de três casos e revisão de literatura
- Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab
- Recurrence and survival after neoadjuvant chemotherapy for locally advanced cervical cancer is dependent on the pathological response
- Expression of hypoxia-inducible factor 1-'alfa' and vascular endothelial growth factor-C in locally advanced breast cancer patients
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
002891231.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
